AstraZeneca's third-quarter profit tops expectations, boosted by cancer drugs

Bloomberg reports that AstraZeneca's third-quarter profit topped expectations, with sales of cancer drugs Imfinzi and Tagrisso also exceeding forecasts. The company outlined a cost-savings plan to invest more in new medicines and reaffirmed its full-year guidance. Barron's says AstraZeneca aims to free up funds for its drug pipeline as it pursues $80 billion in annual revenue by 2030.